USSTOCK.TODAY
Regular Market
Log in Sign up

Growth Strategies and Earnings Outlook for AbbVie and Bristol Myers Squibb

MarketWatch +2 ·

BMY Bristol-Myers Squibb Co
$61.68 +4.84%
View chart & analysis →
  1. 1AbbVie has completed the acquisition of Apogee Therapeutics.
  2. 2Bristol Myers Squibb is expected to see a more than 40% increase in net income and reach $11.2 billion in net income this fiscal year.
  3. 3Bristol Myers Squibb management aims to launch 10 new drugs by 2030.

So what's the key point?

AbbVie acquired Apogee Therapeutics, and Bristol Myers Squibb is expected to increase its profits by more than 40%. Bristol Myers Squibb plans to release many new medicines.

Source MarketWatch +2 · View original ↗

Related 3-line summaries

Bristol Myers Squibb: High Dividend Yield and Turnaround Expectations The Motley Fool +1 · yesterdayBristol Myers Squibb shares fall about 4% on Phase 3 lung disease treatment results BioPharma Dive +1 · Oct 13Bristol Myers Squibb shares surge 6.5% on successful Phase 3 clinical trial results Investing.com +3 · Oct 12
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news